DOCSLIB.ORG

Protocol Supplementary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protocol Supplementary Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf. 28 (clodronic acid or etidronic acid or ibandronic acid or pamidronate or risedronic acid or zoledronic acid).ti,ab,kf. 29 (etidronate or Didrocal or Didronel or Etidrocal or etidronatecal or Etidron or hydroxyethanediphosphonic acid or oxyethylidenediphosphonic acid).ti,ab,kf. 30 (risedronate or Actonel or Atelvia or Benet or Ridron).ti,ab,kf. 31 (zoledronate or Aclasta or Reclast or Zometa).ti,ab,kf. 32 (ibandronate or Bondronat or Boniva or Bonviva or Iasibon or Adronil).ti,ab,kf. 33 (tiludronate or tiludronic acid or Skelid).ti,ab,kf. 34 (pamidronate or Aredia or Aminomux or Pamimed or Ribodroat or Bonin).ti,ab,kf. 35 (clodronate or Bonefos or Clasteon or Ostac Cap or Lodronat or Loron or Lytos or Ostac or Sindronat).ti,ab,kf. 36 exp Bone Density Conservation Agents/ 37 (bone modifying agent* or bone density conservation agent*).ti,ab,kf. 38 (RANKL Inhibitor or denosumab).ti,ab,kf. 39 hormones/ or exp estrogens/ 40 (estrogen or estradiol or estrace or innofem or vagifem or minivelle or yuvafem or premarin or progesterone or estradiol or vivelle or menostar or climara or alora or estraderm or oestradiol or estropipate or ogen or ethinylestradiol or Prempro or premphase or bazedoxifene or duavee or medroxyprogesterone).ti,ab,kf. 41 (phytoestrogen* or Coumestrol or Isoflavone or Isoflavon).ti,ab,kf. 42 (calcitonin or miacalcin or calcimar or cibacalcin or Fortical or thyrocalcitonin or Calcitare).ti,ab,kf. 43 (SERM* or raloxifene or Evista or Optruma or Keoxifene).ti,ab,kf. 44 exp Parathyroid Hormone/ 45 (parathyroid hormone* or parathormone* or teriparatide* or Forteo or Forsteo).ti,ab,kf. 46 Parathyroid Hormone-Related Protein/ 47 exp Anabolic Agents/ 48 (abaloparatide or anabolic agent* or Tymlos).ti,ab,kf. 49 (Sclerostin Inhibitor* or romosozumab or strontium ranelate or ranelic acid or Evenity or Osseor or Protelos).ti,ab,kf. 50 (calcium or vitamin D or nutraceutical or caltrate or ridactate or Calciferol or citracal or posture or Ostoforte or calcitrate or antacids or Cal-Lac or Radiostol or cholecalciferol or alfacalcidol).ti,ab,kf. 51 or/22-50 52 21 and 51 53 exp randomized controlled trial/ 54 exp Randomized Controlled Trials as Topic/ 55 randomized controlled trial.pt. 56 random*.mp. 57 double-blind method/ or single-blind method/ 58 ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or procedure* or method*)).mp. 59 systematic review*.mp. 60 systematic review.pt. 61 meta analys?s.mp. 62 meta-analysis/ or "systematic review"/ 63 or/53-62 64 52 and 63 65 animals/ not (humans/ and animals/) 66 64 not 65 Supplementary 2: CNKI Search Strategy * “+” is equivalent to “OR”, “*” is equivalent to “AND”, “-” is equivalent to “NOT” ((‘bisphosphonate'+'diphosphonates'+'双磷酸盐'+'⼆磷酸盐'+'⼆膦酸盐'+'双膦酸 盐'+'alendronate'+'alendronic acid'+'Fosamax'+'阿伦膦酸'+'阿屈膦酸'+'阿仑膦 酸'+'阿仑特罗'+'阿伦磷酸'+'阿屈磷酸'+'阿仑磷酸'+'阿伦特罗'+'阿仑棒酸'+'阿伦 棒酸'+'福善美'+'固邦'+'天可'+'etidronate'+'etidronic acid’+’EHDP'+'依替膦 酸'+'依替磷酸'+'羟⼄膦酸'+'羟⼄磷酸'+'邦特林'+'依膦'+'正⼤天晴'+'根 德')*('risedronate'+'risedronic acid'+'利塞膦酸'+'利塞磷酸'+'积华固松'+'利噻膦 酸'+'利噻磷酸'+'吉威'+'唯善''zoledronate'+'zoledronic acid'+'Aclasta'+'Zometa'+'唑来膦酸'+'唑来磷酸'+'天晴依泰'+'择泰'+'艾瑞宁'+'健 润'+'震达'+'盖柠'+'卓莱'+'盖柠'+'艾朗'+'因⼒达'+'佐锐 '+'苏奇 '+'博来宁'+'密固 达'+'ibandronate'+'ibandronic acid’+’伊班膦酸’+'伊班磷酸'+'艾本'+'邦罗⼒'+'佳 诺顺')*('tiludronate'+'tiludronic acid'+'Skelid'+'替鲁膦酸'+'替鲁磷酸'+'替鲁罗 酸'+'替⻧屈酸'+'pamidronate'+'pamidronic acid'+'Aredia'+'Bonin'+'帕⽶膦 酸'+'帕⽶磷酸'+'博宁'+'仁怡'+'阿可达'+'clodronate'+'clodronic acid'+'Bonefos'+'氯膦酸钠'+'氯磷酸钠'+'氯屈膦酸'+'氯屈磷酸'+'德维'+'迪盖 纳'+'雅坤宇'+'固令'+'minodronate'+'minodronic acid’+’⽶诺膦酸'+'⽶诺磷 酸')*('RANKL Inhibitor'+'靶向NF-κB受体活化因⼦配体'+'全⼈源抗体'+'RANKL 抗 体’+’denosumab'+'Prolia'+'AMG-162'+'Xgeva'+'Ranmark'+'地诺单抗'+'狄诺塞 ⻨'+'Hormone'+'steroid'+'激素'+'荷尔蒙'+'estrogen'+'雌激素'+'倍美 ⼒')*('calcitonin'+'salmon calcitonin'+'miacalcin'+'降钙素'+'鲑降钙素'+'邦瑞 得'+'固泰宁'+'eel calcitonin'+'porcine calcitonin'+'盖瑞宁'+'翰欣'+'达芬盖'+'考 克'+'密盖息'+'Selective Estrogen Receptor Modulators’+’SERM'+'选择性雌激素 受体调节剂')*('raloxifene'+'Evista'+'Optruma'+'Keoxifene'+'雷洛昔芬'+'盐酸雷洛 昔芬'+'易维特'+'Parathyroid'+'Hormone'+'parathormone'+'PTH'+'甲状旁腺激 素'+'teriparatide'+'Forteo'+'Forsteo'+'特⽴帕肽'+'复泰奥')*('PTHrp'+'甲状旁腺激 素相关蛋⽩类似物'+'abaloparatide'+'Tymlos'+'阿巴帕肽'+'Sclerostin Inhibitor'+'sclerostin antibody’+'硬化素抑制剂'+'硬化素抗 体'+'romosozumab'+'AMG-785'+'Evenity'+'罗莫索单抗')*('strontium ranelate'+'ranelic acid'+'Osseor'+'Protelos'+' '+'雷奈酸锶'+'欧思 美'+'Supplement'+'calcium'+'钙'+'葡萄糖酸钙'+'vitamin D’+’Calciferol’+'cholecalciferol'+'alfacalcidol'+'阿法⻣化醇'+'胆维丁'+'维⽣素 D'))*('glucocorticoid'+'glucosteroid'+'corticosteroid'+'steroid'+'glucocorticostero id'+'糖⽪质'+'糖⽪质素'+'糖⽪质激素'+'激素'+'prednisone'+'肾上腺'+'肾上腺 素'+'肾上腺激素'+'强的松'+'泼尼松'+'prednisolone'+'泼尼松 ⻰'+'hydrocortisone'+'氢化可的松'+'cortisone'+'bethamethasone'+'倍他⽶ 松'+'triamcinolone'+'曲安奈德'+'dexamethasone'+'地塞⽶松'+'氟美松'+'地噻⽶ 松'+'类固醇'+'betamethasone'+'倍他⽶松'+'methylprednisolone'+'甲泼尼⻰'+'甲 基泼尼松⻰'+'甲基强的松⻰'+'甲泼尼松⻰'+'甲强⻰')*('glucocorticoid- induced'+'glucosteroid-induced'+'corticosteroid-induced'+'steroid- induced'+'glucocorticosteroid-induced'+'糖⽪质激素性⻣质疏松'+'糖⽪质激素性 ⻣质疏松'+'GIOP'+'糖⽪质激素诱导⻣质疏松'+'糖⽪质激素引发的⻣质疏 松'+'osteoporosis'+'⻣质疏松'+'fracture'+'Autoimmune disease'+'bone loss’+'⾃ 身免疫性疾病'+'红斑狼疮'+'哮喘')*('randomized controlled trial'+'RCT'+'随 机'+'randomize'+'randomized'+'inferiority'+'双盲'+'control'+'controlled'+'单 盲'+'trial'+'clinical trial’+’placebo’+’开放’+’dummy’+’blind’+’placebo- controlled’+’prospective’+’crossover’+’non-inferiority’+’open-label’+’double- blind’+’triple-blind’+'double-dummy')-('动物'-'animal'-'⿏'-'兔'-'狗'-'⽺') .
Load more

Recommended publications
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The Legally Binding Text Is the Original French Version TRANSPARENCY
    The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP code: 354 366-9) ACTONEL 35 mg, film-coated tablet B/4 (CIP code: 361 577-1) B/12 (CIP code: 366 668-5) ACTONEL 75 mg, film-coated tablet B/2 (CIP code: 384 568-9) B/6 (CIP code: 384 570-3) Applicant: PROCTER & GAMBLE PHARMACEUTICALS risedronate sodium ATC code: M05BA07 List I Date of Marketing Authorisation : ACTONEL 5 mg – 3 May 2000 ACTONEL 30 mg – 3 May 2000 ACTONEL 35 mg – 3 March 2003 ACTONEL 75 mg – 25 March 2008 Reason for request : Re-evaluation of the actual benefit in accordance with article R. 163-21 of the Social Security Code. Medical, Economic and Public Health Assessment Division 1 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient risedronate sodium 1.2. Indications “ACTONEL 5 mg, film-coated tablet - Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. - Treatment of confirmed postmenopausal osteoporosis to reduce the risk of hip fractures. - Prevention of postmenopausal osteoporosis in women at increased risk of osteoporosis. - Maintenance or augmentation of bone mass in postmenopausal women, requiring prolonged (more than 3 months’) systemic corticosteroid therapy with doses ≥ 7.5 mg/day prednisone equivalent. ACTONEL 30 mg, film-coated tablet Treatment of Paget’s disease of bone. ACTONEL 35 mg, film-coated tablet - Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures.
    [Show full text]
  • Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds
    Syracuse University SURFACE Syracuse University Honors Program Capstone Syracuse University Honors Program Capstone Projects Projects Spring 5-1-2012 Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds Seungmo Suh Follow this and additional works at: https://surface.syr.edu/honors_capstone Part of the Biochemistry Commons Recommended Citation Suh, Seungmo, "Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds" (2012). Syracuse University Honors Program Capstone Projects. 151. https://surface.syr.edu/honors_capstone/151 This Honors Capstone Project is brought to you for free and open access by the Syracuse University Honors Program Capstone Projects at SURFACE. It has been accepted for inclusion in Syracuse University Honors Program Capstone Projects by an authorized administrator of SURFACE. For more information, please contact [email protected]. 1 Chapter 1: Background 1.1 Introduction The chemistry of transition metal phosphonates has enormous potential and diverse applications such as gas separation, gas storage or catalyst systems which have been explored in detail.1-6 In contrast, analogous chemistry with the s- block elements has received only a little attention. Calcium was the priority element in our study due to its bioactive properties. Previous studies proved that phosphonates can possibly be used as bone repair materials. 1 The possible applications are only possible with structures with pores or channels for other molecules to enter. Thus, the control of the shape and
    [Show full text]
  • (GE) Review of TA160, 161 and 204; Technologies for The
    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA160, 161 and 204; Technologies for the primary and secondary prevention of osteoporotic fractures1 TA160 and TA161 give guidance on alendronate, risedronate, etidronate, strontium ranelate, raloxifene and teriparatide, and were re-issued after the Judicial Review in January 2011. TA204 gives guidance on denosumab and was issued in October 2010. TA160 and TA161 were to be considered for review after the short clinical guideline on risk assessment has been published. TA204 was to be considered for review at the same time that TA160 and TA161 are considered for review. In August 2012 the clinical guideline on assessing the risk of fragility fractures in people with osteoporosis was published (CG146). In July 2012 Guidance Executive agreed to reschedule the review proposal for the above technology appraisals so that we can explore how treatment intervention thresholds from the technology appraisals can be aligned to the assessment of absolute fracture risk recommended in CG146, and to carry out a feasibility study through NICE’s Decision Support Unit. 1 Review of TA160; Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, TA161; Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, and TA204; Denosumab for the prevention of osteoporotic
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Denosumab, Raloxifene, Romosozumab and Teriparatide to Prevent Osteoporotic Fragility Fractures: a Systematic Review and Economic Evaluation
    Journals Library Health Technology Assessment Volume 24 • Issue 29 • June 2020 ISSN 1366-5278 Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation Sarah Davis, Emma Simpson, Jean Hamilton, Marrissa Martyn-St James, Andrew Rawdin, Ruth Wong, Edward Goka, Neil Gittoes and Peter Selby DOI 10.3310/hta24290 Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation Sarah Davis ,1* Emma Simpson ,1 Jean Hamilton ,1 Marrissa Martyn-St James ,1 Andrew Rawdin ,1 Ruth Wong ,1 Edward Goka ,1 Neil Gittoes 2 and Peter Selby 3 1Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK 2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK 3School of Medical Sciences, University of Manchester, Manchester, UK *Corresponding author Declared competing interests of authors: Neil Gittoes reports personal fees for being a member of the advisory board to Union Chimique Belge (UCB) S.A. (Brussels, Belgium) and personal fees for contributing to educational meeting sponsored by Eli Lilly and Company (Indianapolis, IN, USA), outside the submitted work. He is also a trustee of the National Osteoporosis Society, a member of the advisory board of the National Osteoporosis Guideline Group and Deputy Chairperson of the Specialised Endocrinology Clinical Reference Group, NHS England. Published June 2020 DOI: 10.3310/hta24290 This report should be referenced as follows: Davis S, Simpson E, Hamilton J, James MM-S, Rawdin A, Wong R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    [Show full text]
  • Tiludronate 1105 Osteoporosis
    Strontium Ranelate/Tiludronate 1105 Osteoporosis. Strontium ranelate, given orally with calcium temic hypersensitivity reactions should be borne in mind. Hyper- Data on combination therapy are limited, but some studies sug- and vitamin D supplements, has been found to reduce the risk of calcaemia may develop with teriparatide or the acetate and it is gest that teriparatide with HRT is more effective than HRT vertebral1 and non-vertebral2 fractures in postmenopausal wom- therefore contra-indicated in patients with pre-existing hypercal- alone.9 The effect of teriparatide with the antiresorptive bisphos- en with osteoporosis. A pooled analysis of data from these 2 caemia. phonates has yet to be determined.2,6,9,10 Although there is some studies concluded that strontium ranelate reduced both vertebral suggestion that teriparatide still increases bone formation after 3 Teriparatide is contra-indicated in patients with severe renal im- 9 and non-vertebral fractures in patients aged 80 years or older. pairment and should be used with caution with those with mod- treatment with alendronate, a study in men found that, when Protection against fractures was detected within 12 months, and erate impairment. given together, alendronate impaired the anabolic effects of teri- sustained throughout 3 years of treatment. Hip fractures were paratide.11 For this reason, some consider that teriparatide be also reduced over 3 years, but this did not reach statistical signif- There have been reports of osteosarcoma in rats given teripara- started immediately after stopping bisphosphonates.10 It has been icance; the authors concluded that the analysis may not have tide and patients who may be at increased risk, including those suggested that the degree of suppression of bone turnover before been sufficiently powered in this respect.
    [Show full text]
  • WO 2015/123734 Al 27 August 2015 (27.08.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/123734 Al 27 August 2015 (27.08.2015) P O P C T (51) International Patent Classification: (74) Agent: FB RICE; Level 23, 44 Market Street, Sydney, C08B 3/02 (2006.01) C07H 13/06 (2006.01) New South Wales 2000 (AU). C07H 13/04 (2006.0 1) A61K 9/14 (2006.0 1) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/AU2015/050069 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 23 February 2015 (23.02.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 2014900566 2 1 February 2014 (21.02.2014) AU TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicants: THE UNIVERSITY OF SYDNEY (84) Designated States (unless otherwise indicated, for every [AU/AU]; Sydney, Sydney, New South Wales 2006 (AU).
    [Show full text]
  • Date Database Search Strategy Filters Results Results After Duplicates
    Date Database Search Strategy Filters Results Results after Duplicates Removed 12/12/2018 PubMed (("Patient Participation"[Mesh] OR "Patient Participation" OR “Patient Filters: 120 108 Involvement” OR “Patient Empowerment” OR “Patient Participation Rates” English OR “Patient Participation Rate” OR “Patient Activation” OR “Patient Engagement” OR "Refusal to Participate"[Mesh] OR "Refusal to Participate" OR "Self Care"[Mesh] OR "Self Care" OR "Self-Care" OR “Well-being” OR Wellbeing OR “well being” OR "Walking"[Mesh] OR Walking OR Walk OR Walked OR Ambulation OR "Gait"[Mesh] OR Gait OR Gaits OR "Mobility Limitation"[Mesh] OR "Mobility Limitation" OR Mobility OR “Mobility Limitations” OR “Ambulation Difficulty” OR “Ambulation Difficulties” OR “Difficulty Ambulation” OR “Ambulatory Difficulty” OR “Ambulatory Difficulties” OR “Difficulty Walking” OR "Dependent Ambulation"[Mesh] OR "Dependent Ambulation" OR “functional status” OR “functional state” OR "Community Participation"[Mesh] OR "Community Participation" OR “Community Involvement” OR “Community Involvements” OR “Consumer Participation” OR “Consumer Involvement” OR “Public Participation” OR “Community Action” OR “Community Actions” OR "Social Participation"[Mesh] OR "Social Participation" OR "Activities of Daily Living"[Mesh] OR "Activities of Daily Living" OR ADL OR “Daily Living Activities” OR “Daily Living Activity” OR “Chronic Limitation of Activity” OR "Quality of Life"[Mesh] OR "Quality of Life" OR “Life Quality” OR “Health- Related Quality Of Life” OR “Health Related Quality Of
    [Show full text]
  • Re-Evaluated Data of Dissociation Constants of Alendronic, Pamidronic and Olpadronic Acids
    Cent. Eur. J. Chem. • 7(1) • 2009 • 8-13 DOI: 10.2478/s11532-008-0099-z Central European Journal of Chemistry Re-evaluated data of dissociation constants of alendronic, pamidronic and olpadronic acids Invited Paper Alexander P. Boichenko1, Vadim V. Markov1, Hoan Le Kong1, Anna G. Matveeva2, Lidia P. Loginova1* 1Department of Chemical Metrology, Kharkov V.N. Karazin National University, 61077 Kharkov, Ukraine. 2A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation Received 01 April 2008; Accepted 23 October 2008 Abstract: The dissociation constants of (4-amino-1-hydroxybutylidene)bisphosphonic (alendronic) acid, (3-(dimethylamino)-1- hydroxypropylidene)bisphosphonic (olpadronic) acid and (3-amino-1-hydroxypropylidene)bisphosphonic (pamidronic) acid were obtained in aqueous solutions (0.10 М КСl) and micellar solutions of cetylpyridinium chloride (0.10 М CPC) at 25.0°C. With the exception of the third dissociation constant of alendronic acid, the dissociation constants of alendronic, olpadronic and pamidronic acids in aqueous solutions matched literature data. The possibility of sodium alendronate determination by acid-base titration by NaOH solution was theoretically grounded on the basis of re-evaluated data of alendronic acid dissociation constants. Keywords: Alendronate • Olpadronate, pamidronate, dissociation constant • Micellar media effect © Versita Warsaw and Springer-Verlag Berlin Heidelberg. 1. Introduction spectrometric [12], refractive index [13] and Sodium salts of (4-amino-1-hydroxybutylidene) conductometric [14] detection have been proposed. bisphosphonic (alendronic) acid, (3-(dimethylamino)- The anion-exchange chromatography with refractive 1-hydroxypropylidene)bisphosphonic (olpadronic) acid index detection is recommended by British and (3-amino-1-hydroxypropylidene)bisphosphonic Pharmacopoeia for the determination of sodium (pamidronic) acid are successfully used for the medical alendronate [15].
    [Show full text]
  • Phvwp Class Review Bisphosphonates and Osteonecrosis of the Jaw (Alendronic Acid, Clodronic Acid, Etidronic Acid, Ibandronic
    PhVWP Class Review Bisphosphonates and osteonecrosis of the jaw (alendronic acid, clodronic acid, etidronic acid, ibandronic acid, neridronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid), SPC wording agreed by the PhVWP in February 2006 Section 4.4 Pamidronic acid and zoledronic acid: “Osteonecrosis of the jaw has been reported in patients with cancer receiving treatment regimens including bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. Many had signs of local infection including osteomyelitis. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene). While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.” Remaining bisphosphonates: “Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelits) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphophonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphophonates. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g.
    [Show full text]